Yeah, I'm not sure if I would call it "incompetence", but it wouldn't be hard for the U.S. public or private sectors to afford MMR vaccine doses for the whole population (or merely the portion that has missed doses on the recommended schedule). Those doses would have a super-low opportunity cost.